Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that Celgene will dominate the multiple myeloma (MM) drug market through 2011. Celgene's Thalomid and, later, its analogues will revolutionize the second-line treatment market for MM. According to a new Pharmacor study entitled Multiple Myeloma, Thalomid will generate $50 million in sales in 2006 and thalidomide analogues will garner sales of $81 million in 2011.

"Although Thalomid's dominance will be short-lived, Celgene will still dominate the market by producing analogues of thalidomide that will prove themselves to be equally potent, but better tolerated than Thalomid in Phase II and III clinical trials," said Andrew Paramore, analyst at Decision Resources.

The study also forecasts that the promise of orphan drug status will encourage many companies to continue to invest in research and development of drugs for MM. Orphan drug status grants drug developers up to ten years of market exclusivity for drugs that treat specific indications affecting small numbers of patients.

"Orphan drug status has already resulted in a number of novel agents for MM that will launch between 2001 and 2006, and will lead to many more in the future," continued Mr. Paramore.

Disease Background-Multiple Myeloma

Multiple myeloma is an incurable hematological cancer associated with extremely high morbidity and mortality. The incidence of MM is rising in the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) as a result of the changing age structure in developed countries. Despite the acute need for therapies that can reduce mortality and alleviate suffering, the comparatively low incidence of MM, coupled with the high cost of drug development and the challenge of discovering a successful treatment, has limited advances in treatment. Only a small minority of young, fit patients are eligible for the most efficacious treatment of high-dose therapy followed by stem-cell rescue. The majority of patients are treated with combination chemotherapy regimens that have poor response rates and high toxicity.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Multiple Myeloma is an Onkos study.

About Decision Resources

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at www.decisionresources.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

Despite Negative Impact of WHI and HERS II Studies, the Hormone Replacement Therapy Market Will Experience Robust Growth

View Now